About SolasCure
SolasCure is a company based in Cardiff (United Kingdom) founded in 2017. SolasCure has raised $34.12 million across 4 funding rounds from investors including Brain Biotech, Development Bank of Wales and Eva Pharma. The company has 11 employees. SolasCure offers products and services including Aurase Wound Gel. SolasCure operates in a competitive market with competitors including BioMonde, EZ Debride, XSONX and Regenerative Wound Therapies, among others.
- Headquarter Cardiff, United Kingdom
- Employees 11
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website solascure.com
- Social LinkedIn
- Legal Name Solascure Limited
- Date of Incorporation 20 Jun, 2017
- Jurisdiction CAMBRIDGE, ENGLAND
- Total Equity Funding$34.12M (USD)
in 4 rounds
- Latest Funding Round$514.76K (USD), Grant
Mar 2024
- InvestorsBrain Biotech
& 9 more
- Employee Count11
Products & Services of SolasCure
SolasCure offers a comprehensive portfolio of products and services, including Aurase Wound Gel.
Enzymatic gel for debriding chronic wounds and promoting healing.
Funding Insights of SolasCure
SolasCure has successfully raised a total of $34.12M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $514.76 thousand completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $34.12M
- Total Rounds 4
- Last Round Grant — $514,759
- First Round $20.79M
(Aug 2021)
- Investors Count 10
All 4 funding rounds of SolasCure with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $514,759 | Grant | – | – | |
| Mar 2023 | $13.33M | Series B | – | Seneca | |
| Jun 2022 | – | Grant | – | – | |
| Aug 2021 | $20.79M | Series A | – | – |
10 investors in total: 8 institutional and 2 angel.
Investors in SolasCure
SolasCure has secured backing from 10 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Brain Biotech, Development Bank of Wales and Eva Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
- | – | bionovacapital.com | - | |
Provider of equity funding and business & property development loans | 2001 | developmentbank.wales | Wrexham, United Kingdom | |
Seneca Partners is engaged in tax-advantaged investment services. | – | senecapartners.co.uk | Haydock, United Kingdom | |
Developr of bio-based products and natural compounds for biotechnological solutions | 1993 | brain-biotech.com | Zwingenberg, Germany | |
Pharmaceutical products are manufactured and healthcare solutions are provided worldwide. | 1997 | evapharma.com | Giza, Egypt | |
Offers tax-efficient investments and portfolios for high net worth individuals. | 2016 | wealthclub.co.uk | Bristol, United Kingdom | |
- | – | innovateuk.gov.uk | - | |
JM Jonathan Milner | British angel investor, founder of Abcam, active in biotech and life sciences. | – | unknown_fc8e3a022a024cc1a | - |
FF François Fournier | - | – | unknown_cf9152eb5bd0434fb | - |
Investor details for SolasCure
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SolasCure
9 people are tracked at SolasCure (8 in leadership, 1 in team); the tracked headcount is 11.
| Name | Role | Group |
|---|---|---|
Adam Rytko | Quality Assurance Director | Leadership |
Bela Kelety | Chief Technology Officer | Leadership |
Charles Bruce | Non Executive Director | Leadership |
David Fairlamb | Chief Development Officer (cdo) | Leadership |
Lee Harle | Chief Executive Officer | Leadership |
Benjamin Newmark | President | Leadership |
Oliver Schofield | Chief Financial Officer | Leadership |
David G. | Chief Medical Officer | Leadership |
Celia Harrison | Consultant | Team |
Complete people profiles for SolasCure
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SolasCure
3 dated milestones of SolasCure across 7 years, from founding to its latest funding, stage changes and deals.
- Founded SolasCure is founded.
- Funding First funding round of $20.8M.
- Funding Latest funding round, Grant, of $515K.
Competitors of SolasCure
SolasCure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioMonde, EZ Debride, XSONX and Regenerative Wound Therapies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biomonde.com | 2014 | Gainesville, United States | $5.9M | – | Larva therapy is manufactured for debridement of non-healing wounds. | |
| ezdebride.com | 2015 | Schertz, United States | $585,000 | – | A patent-pending wound debridement tool is developed by EZ Debride. | |
| xsonx.com | 2020 | Charlotte, United States | – | – | Develops wound hygiene systems using micro-vibrational technology to enhance healing. | |
| regenerativewoundtherapies.in | 2019 | Bengaluru, India | – | – | Offers advanced wound management through innovative medical devices for healthcare. |
Detailed competitors of SolasCure
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SolasCure
The website of SolasCure (solascure.com) receives about 1K visits a month.
- Monthly visits1K
Latest news on Solascure
Complete news archive for SolasCure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SolasCure
10 companies that operate in the same segment as SolasCure (Wound Care), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Fish-skin acellular dermal matrix technology is provided for wound treatments. | 2007 | Isafjordur, Iceland | USD 93.11 M | – | 150 | |
Developer of advanced haemostat and wound care dressing products | 2008 | Ahmedabad, Gujarat, India | USD 42.71 M | USD 2.88 M | 70 | |
Oxygen-based wound therapy devices are developed for healing non-healing wounds. | 2003 | Waterbeach, Cambridgeshire, United Kingdom | USD 68.39 M | – | – | |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | – | USD 418.63 M | 837 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M | – | – | |
Regenerative therapies for wound care are developed and commercialized. | 1985 | Canton, Ohio, United States | USD 30 M | USD 564.17 M | 869 | |
Cold plasma solutions for wound treatment are developed. | 2013 | Eindhoven, Noord-brabant, Netherlands | USD 7.06 M | – | – | |
Point-of-care devices for wound bacterial assessment are provided. | 2013 | Toronto, Ontario, Canada | USD 43.2 M | – | 49 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SolasCure
SolasCure was founded in 2017 and raised its 1st funding round 4 years after it was founded.
SolasCure is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
SolasCure is a funded company, having raised a total of $34.12M across 4 funding rounds to date. The company's 1st funding round was a Series A of $20.79M, raised on Aug 2021.
SolasCure has 11 employees.
SolasCure was founded in 2017 in Cardiff, United Kingdom. Products for wound care are developed within the medical biotechnology sector. Operations center on innovative hydrogels for debridement and healing. The primary product, Aurase, incorporates an active enzyme that has been isolated and cloned from medical maggots traditionally used for wound cleaning. Focus remains on clinical applications for chronic and acute wounds.
SolasCure's top competitors include BioMonde, EZ Debride and XSONX.
SolasCure offers Aurase Wound Gel.
SolasCure has 10 investors. Key investors include Brain Biotech, Development Bank of Wales, Eva Pharma, Seneca Partners, and Jonathan Milner.
SolasCure operates through Solascure Limited.